…
Nuchev Limited engages in the nutrition and wellness business across consumer, practitioner, distribution, and digital channels in Australia, China, Vietnam, and New Zealand. It offers goat-milk food and beverages; natural liquid vitamins; skincare products; and functional nutrition for weight wellness and vitality under the Oli6, Brauer, Skin Physics, and Rapid Loss brands. The company also provides clinically validated formulations, practitioner education, and professional support; bioavailable, well-tolerated formulations for energy, muscle, and nervous system support; alkaline mineral formulations; homeopathic solutions; liquid formulations; and herbal remedies under the Bio-Practica, Magnesium Diasporal, Basica, Heel, Brauer Professional, and Medicine Tree brands. In addition, it offers children's snacking products, goat functional food products, and full cream goat milk powder formats. The company sells its products through pharmacy, grocery, retail, and e-commerce channels; and digital platforms, as well as healthcare practitioners, clinics, health food stores, and other specialist channels. Nuchev Limited was incorporated in 2013 and is headquartered in Melbourne, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Nuchev Ltd is an Australian company focused on developing and supplying cannabinoid-based medicines and wellness products for clinical and consumer use. Long-term growth may be supported by rising medical cannabis acceptance, expansion of product portfolios and clinical evidence, and opportunities in domestic and export markets, which could make the company attractive to investors seeking regulated cannabis exposure.
Key risks include regulatory shifts affecting market access and approvals, competitive pressure from larger pharmaceutical and consumer firms, clinical or product development setbacks, and capital or execution constraints.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -7.39M | -3.82M | -7.32M | -8.81M | -11.11M |
| Net income | -7.39M | -3.82M | -7.32M | -8.81M | -11.81M |
| Selling general administrative | 15.97M | 3.35M | 7.53M | 7.04M | 6.10M |
| Selling and marketing expenses | - | 4.98M | 3.41M | 3.06M | 5.51M |
| Gross profit | 3.19M | 10.86M | 3.63M | 1.66M | 2.78M |
| Reconciled depreciation | 0.62M | 0.73M | 0.11M | 0.19M | 0.20M |
| Ebit | -5.39M | -4.35M | -7.29M | -8.19M | -10.40M |
| Ebitda | -4.76M | -3.73M | -7.18M | -8.00M | -10.20M |
| Depreciation and amortization | 0.62M | 0.63M | 0.11M | 0.19M | 0.20M |
| Operating income | -5.39M | -3.57M | -6.46M | -8.19M | -10.40M |
| Other operating expenses | 31.07M | 26.51M | 17.73M | 17.20M | 20.40M |
| Interest expense | 0.28M | 0.04M | 0.03M | 0.07M | 0.01M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 0.11M | 0.17M | 0.09M | 0.01M | 0.01M |
| Net interest income | -0.17M | 0.14M | 0.06M | -0.07M | -0.02M |
| Income tax expense | - | - | 0.00M | 0.29M | 0.70M |
| Total revenue | 25.68M | 22.94M | 11.34M | 8.79M | 9.72M |
| Total operating expenses | 8.58M | 14.43M | 10.02M | 10.07M | 13.46M |
| Cost of revenue | 22.49M | 12.08M | 7.72M | 7.14M | 6.95M |
| Total other income expense net | -2.00M | -0.25M | -0.86M | -0.33M | -0.71M |
| Net income from continuing ops | -7.39M | -3.82M | -7.32M | -8.81M | -11.11M |
| Net income applicable to common shares | - | -3.82M | -7.32M | -8.81M | -11.11M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 19.60M | 17.39M | 20.09M | 15.32M | 17.75M |
| Intangible assets | 1.99M | 2.34M | - | 0.00M | 0.51M |
| Other current assets | 1.18M | 0.32M | 0.49M | 0.01M | 0.01M |
| Total liab | 13.67M | 6.16M | 5.34M | 2.51M | 1.92M |
| Total stockholder equity | 5.93M | 11.23M | 14.75M | 12.82M | 15.83M |
| Deferred long term liab | - | - | - | - | 0.26M |
| Other current liab | 5.60M | 4.16M | 3.25M | 0.01M | 1.01M |
| Common stock | 113.23M | 111.04M | 111.06M | 101.86M | 96.04M |
| Capital stock | 113.23M | - | - | 101.86M | 96.04M |
| Retained earnings | -109.46M | -102.07M | -98.25M | -90.93M | -82.12M |
| Other liab | - | - | - | 0.08M | 0.08M |
| Good will | - | 1.87M | 4.22M | - | - |
| Other assets | - | - | 0.00M | 0.08M | 0.71M |
| Cash | 2.13M | 3.61M | 7.61M | 7.48M | 5.11M |
| Cash and equivalents | - | - | - | 0.33M | 0.33M |
| Total current liabilities | 9.11M | 5.39M | 4.94M | 2.19M | 1.84M |
| Current deferred revenue | 0.02M | - | - | 1.43M | - |
| Net debt | 2.07M | -3.21M | -7.29M | -7.19M | -4.96M |
| Short term debt | 0.21M | 0.12M | 0.09M | 0.05M | 0.15M |
| Short long term debt total | 4.19M | 0.39M | 0.32M | 0.28M | 0.15M |
| Other stockholder equity | - | - | - | 1.89M | 1.92M |
| Property plant equipment | - | - | - | 0.35M | 0.13M |
| Total current assets | 16.60M | 12.40M | 15.22M | 14.60M | 16.66M |
| Long term investments | 0.15M | - | - | 0.32M | 0.38M |
| Net tangible assets | - | - | - | 12.82M | 15.58M |
| Short term investments | - | - | - | 0.02M | 0.01M |
| Net receivables | 5.90M | 2.93M | 2.13M | 0.67M | 1.66M |
| Long term debt | 3.50M | - | - | - | - |
| Inventory | 7.39M | 5.54M | 4.98M | 5.31M | 9.35M |
| Accounts payable | 3.28M | 1.11M | 1.60M | 0.70M | 0.67M |
| Accumulated other comprehensive income | 2.16M | 2.26M | 1.94M | 1.89M | 1.92M |
| Non currrent assets other | 0.08M | 0.08M | 0.08M | 0.06M | 0.07M |
| Non current assets total | 3.01M | 4.99M | 4.87M | 0.73M | 1.09M |
| Capital lease obligations | 0.69M | - | - | 0.28M | 0.15M |
| Long term debt total | - | - | - | 0.24M | 0.00M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | - | -0.14M | -2.19M | -0.13M | -0.91M |
| Change to liabilities | - | - | - | 0.33M | 0.29M |
| Total cashflows from investing activities | -0.08M | -0.14M | -2.19M | -0.13M | -0.91M |
| Net borrowings | 3.50M | - | - | -0.15M | -0.12M |
| Total cash from financing activities | 5.27M | -0.12M | 6.06M | 5.78M | -0.12M |
| Change to operating activities | - | - | - | 0.00M | -0.01M |
| Net income | -7.39M | -3.82M | -7.32M | -8.81M | -11.81M |
| Change in cash | -1.48M | -4.00M | 0.13M | 2.37M | -9.40M |
| Begin period cash flow | 3.61M | 7.61M | 7.48M | 5.11M | 14.51M |
| End period cash flow | 2.13M | 3.61M | 7.61M | 7.48M | 5.11M |
| Total cash from operating activities | -6.64M | -3.74M | -3.73M | -3.26M | -11.61M |
| Issuance of capital stock | 1.93M | - | 6.51M | 6.53M | - |
| Depreciation | 0.62M | 0.73M | 0.11M | 0.14M | 0.20M |
| Other cashflows from investing activities | - | -0.03M | 0.00M | 0.00M | -1.08M |
| Change to inventory | -2.01M | -0.40M | 2.32M | 4.05M | 2.00M |
| Change to account receivables | -3.56M | -0.77M | -0.26M | 0.33M | -0.57M |
| Sale purchase of stock | - | -0.02M | -0.29M | -0.60M | 0.00M |
| Other cashflows from financing activities | -0.16M | -0.02M | -0.09M | -0.15M | -0.12M |
| Change to netincome | - | - | - | 0.64M | 0.91M |
| Capital expenditures | 0.02M | 0.18M | 0.01M | 0.13M | 0.01M |
| Change in working capital | -2.14M | -1.26M | 3.27M | 0.05M | 0.13M |
| Stock based compensation | - | 0.32M | 0.06M | - | - |
| Other non cash items | 2.26M | 0.30M | 0.15M | - | 11.61M |
| Free cash flow | -6.66M | -3.93M | -3.74M | -3.38M | -11.62M |
Sector: Consumer Defensive Industry: Packaged Foods
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NUC Nuchev Ltd |
- -% |
0.06 | - | - | 0.37 | 1.85 | 0.51 | -0.60 |
| A2M The a2 Milk Company Ltd |
-0.07 0.96% |
7.19 | 29.04 | 28.74 | 2.68 | 5.94 | 2.85 | 17.82 |
| BGA Bega Cheese Ltd |
-0.02 0.30% |
6.74 | 35.61 | 22.94 | 0.52 | 1.93 | 0.60 | 11.82 |
| CBO Cobram Estate Olives Ltd |
-0.06 2.26% |
2.59 | - | - | 4.79 | 2.48 | 6.63 | 185.44 |
| RIC Ridley Corporation Ltd |
0.02 0.74% |
2.74 | 38.29 | 13.42 | 0.35 | 2.01 | 0.53 | 4.50 |
Nuchev Limited engages in the nutrition and wellness business across consumer, practitioner, distribution, and digital channels in Australia, China, Vietnam, and New Zealand. It offers goat-milk food and beverages; natural liquid vitamins; skincare products; and functional nutrition for weight wellness and vitality under the Oli6, Brauer, Skin Physics, and Rapid Loss brands. The company also provides clinically validated formulations, practitioner education, and professional support; bioavailable, well-tolerated formulations for energy, muscle, and nervous system support; alkaline mineral formulations; homeopathic solutions; liquid formulations; and herbal remedies under the Bio-Practica, Magnesium Diasporal, Basica, Heel, Brauer Professional, and Medicine Tree brands. In addition, it offers children's snacking products, goat functional food products, and full cream goat milk powder formats. The company sells its products through pharmacy, grocery, retail, and e-commerce channels; and digital platforms, as well as healthcare practitioners, clinics, health food stores, and other specialist channels. Nuchev Limited was incorporated in 2013 and is headquartered in Melbourne, Australia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Ben Dingle | Founder & Exec. Director | NA |
| Mr. Michael Myers | Chief Financial Officer | NA |
| Mr. Gregory Norman Sean Kerr | Chief Exec. Officer | NA |
| Ms. Lisa Saunders | Chief Marketing Officer | NA |
| Ms. Tamara Barr | Company Sec. | NA |
| Mr. Michael Myers | Interim CEO & CFO | NA |
| Mr. Scott Koetsier | Head of Sales & Business Development | NA |
| Ms. Tamara Monica Barr | Company Secretary | NA |
| Mr. Michael Myers | Interim CEO & CFO | NA |
| Mr. Scott Koetsier | Head of Sales & Business Development | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.